Literature DB >> 35020832

Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.

Ahmed A Kolkailah1, Stephen D Wiviott2, Itamar Raz3, Sabina A Murphy2, Ofri Mosenzon4, Deepak L Bhatt2, Lawrence A Leiter5, John P H Wilding6, Ingrid Gause-Nilsson7, Marc S Sabatine2, Darren K McGuire1,8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35020832      PMCID: PMC8914433          DOI: 10.2337/dc21-1668

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  5 in total

Review 1.  Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.

Authors:  Motoaki Sano; Shinichi Goto
Journal:  Circulation       Date:  2019-04-23       Impact factor: 29.690

2.  How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.

Authors:  Silvio E Inzucchi; Bernard Zinman; David Fitchett; Christoph Wanner; Ele Ferrannini; Martin Schumacher; Claudia Schmoor; Kristin Ohneberg; Odd Erik Johansen; Jyothis T George; Stefan Hantel; Erich Bluhmki; John M Lachin
Journal:  Diabetes Care       Date:  2017-12-04       Impact factor: 19.112

3.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

4.  Effect of dapagliflozin on anaemia in DAPA-HF.

Authors:  Kieran F Docherty; James P Curtain; Inder S Anand; Olof Bengtsson; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Morten Schou; Mikaela Sjöstrand; Scott D Solomon; Pardeep S Jhund; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2021-03-22       Impact factor: 15.534

5.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

  5 in total
  1 in total

1.  Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy.

Authors:  Kamilya A Schumacher; Aidar R Gosmanov
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.